Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARC BERNSTEIN

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1851333587
CMS profile
83695
Location
SLIDELL, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,495.26

104 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,480.53 103
Education $14.73 1

By paying entity

PY2020 · entire year · sorted by reported total

Page 3 of 3; records 101–104 of 104 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARC BERNSTEIN

NPI 1851333587 · CMS profile ID 83695

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

SLIDELL, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–104 of 104 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1851333587?year=2020&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARC BERNSTEIN, NPI 1851333587, CMS profile ID 83695. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–104 of 104 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851333587?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MARC BERNSTEIN, NPI 1851333587, CMS profile ID 83695. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–104 of 104 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851333587?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MARC BERNSTEIN, NPI 1851333587, CMS profile ID 83695, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–104 of 104 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1851333587?year=2020&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

104 matching records · $1,495.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 104 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–104 of 104.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $10.0801/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725572436 CMS
Lundbeck LLC $15.5401/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747503655 CMS
Janssen Pharmaceuticals, Inc $17.1601/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719280095 CMS
AstraZeneca Pharmaceuticals LP $12.3501/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736116405 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,555.66 152
PY2020 $1,495.26 104
PY2021 $2,763.95 144
PY2022 $2,129.17 151
PY2023 $3,284.80 132
PY2024 $1,880.24 116
PY2025 $1,973.44 110

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $428,785.67 125
PY2024 Recipient $45,424.00 1
PY2024 Principal investigator $296,572.58 29
PY2023 Principal investigator $282,073.94 36
PY2022 Principal investigator $159,913.35 25
PY2021 Principal investigator $287,609.81 133
PY2020 Principal investigator $319,223.54 241
PY2019 Principal investigator $349,949.75 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

125 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $1,878.00 12/24/2025 Non-covered Recipient Entity
DRS ITELD BERNSTEIN & ASSOC DBA LA HEART CTR
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246640875
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 12/15/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628833
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 12/15/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628835
Principal investigator 1 Boehringer Ingelheim International GmbH $2,630.00 12/15/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628837
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 12/15/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628839
Principal investigator 1 Janssen Research & Development, LLC $2,573.00 12/12/2025 Non-covered Recipient Entity
Louisiana Heart Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224758
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220628681
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628829
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628831
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 11/26/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220792515
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 11/19/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628823
Principal investigator 1 Boehringer Ingelheim International GmbH $2,097.00 11/19/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628825
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 11/19/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628827
Principal investigator 1 Janssen Research & Development, LLC $8,380.00 11/19/2025 Non-covered Recipient Entity
Louisiana Heart Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224751
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 11/11/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994421
Principal investigator 1 Janssen Research & Development, LLC $2,181.00 11/07/2025 Non-covered Recipient Entity
Louisiana Heart Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224781
Principal investigator 1 Janssen Research & Development, LLC $864.00 11/03/2025 Non-covered Recipient Entity
Louisiana Heart Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224852
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220628677
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220628679
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628819
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628821
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 10/27/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220628683
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220628685
Principal investigator 1 Boehringer Ingelheim International GmbH $2,276.00 10/20/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628815
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/20/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628817
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/02/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628809
Principal investigator 1 Boehringer Ingelheim International GmbH $2,423.00 10/02/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628811
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/02/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628813
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220628669
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 10/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220628671
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 10/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220628673
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 10/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220628675
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628805
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628807
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 09/24/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628797
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 09/24/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628799
Principal investigator 1 Boehringer Ingelheim International GmbH $2.61 09/24/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628801
Principal investigator 1 Boehringer Ingelheim International GmbH $5.64 09/24/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628803
Principal investigator 1 Janssen Research & Development, LLC $4,783.00 09/19/2025 Non-covered Recipient Entity
Louisiana Heart Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224765
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,000.00 09/18/2025 Non-covered Recipient Entity
ITELD BERNSTEIN ASSOCIATES DBA LOUISIANA HEART CENTER
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190309482
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628771
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628773
Principal investigator 1 Janssen Research & Development, LLC $7,352.00 08/25/2025 Non-covered Recipient Entity
Louisiana Heart Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224792
Principal investigator 1 Amgen Inc. $7,500.00 08/23/2025 Non-covered Recipient Entity
DRS ITELD BERNSTEIN & ASSOC DBA LA HEART CTR
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246640883
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 08/20/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628781
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 08/20/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994419
Principal investigator 1 Boehringer Ingelheim International GmbH $2,380.00 08/13/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628779
Principal investigator 1 Boehringer Ingelheim International GmbH $2,758.00 08/13/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628783
Principal investigator 1 Boehringer Ingelheim International GmbH $1,720.00 08/13/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628785
Principal investigator 1 Boehringer Ingelheim International GmbH $2,380.00 08/13/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628787
Principal investigator 1 Boehringer Ingelheim International GmbH $2,758.00 08/13/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628789
Principal investigator 1 Boehringer Ingelheim International GmbH $1,720.00 08/13/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628791
Principal investigator 1 Boehringer Ingelheim International GmbH $2,423.00 08/13/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628793
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628767
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628769
Principal investigator 1 Amgen Inc. $1,592.24 07/28/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER - HAMMOND
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246643645
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 07/28/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628795
Principal investigator 1 Boehringer Ingelheim International GmbH $2,828.00 07/25/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628761
Principal investigator 1 Boehringer Ingelheim International GmbH $2,310.00 07/25/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628763
Principal investigator 1 Boehringer Ingelheim International GmbH $1,660.00 07/25/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628765
Principal investigator 1 Janssen Research & Development, LLC $2,837.00 07/23/2025 Non-covered Recipient Entity
Louisiana Heart Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224834
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 07/03/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994417
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628775
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628777
Principal investigator 1 Amgen Inc. $5,118.98 06/24/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER - HAMMOND
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246643656
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 06/24/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628759
Principal investigator 1 Janssen Research & Development, LLC $1,822.00 06/23/2025 Non-covered Recipient Entity
Louisiana Heart Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224811
Principal investigator 1 Janssen Research & Development, LLC $6,601.00 06/20/2025 Non-covered Recipient Entity
Louisiana Heart Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224735
Principal investigator 1 Amgen Inc. $341.00 06/05/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246643659
Principal investigator 1 Boehringer Ingelheim International GmbH $2,828.00 06/04/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628735
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 06/04/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628737
Principal investigator 1 Boehringer Ingelheim International GmbH $2,828.00 06/04/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628739
Principal investigator 1 Boehringer Ingelheim International GmbH $2,097.00 06/04/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628741
Principal investigator 1 Boehringer Ingelheim International GmbH $2,179.00 06/04/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628743
Principal investigator 1 Boehringer Ingelheim International GmbH $2,310.00 06/04/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628745
Principal investigator 1 Amgen Inc. $6,121.00 06/03/2025 Non-covered Recipient Entity
DRS ITELD BERNSTEIN & ASSOC DBA LA HEART CTR
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246640881
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628731
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628733
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 05/27/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628751
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 05/27/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628753
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 05/27/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628755
Principal investigator 1 Boehringer Ingelheim International GmbH $3.76 05/27/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628757
Principal investigator 1 Janssen Research & Development, LLC $5,719.00 05/21/2025 Non-covered Recipient Entity
Louisiana Heart Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224772
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628727
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628729
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 04/30/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994415
Principal investigator 1 Boehringer Ingelheim International GmbH $1,660.00 04/25/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628725
Principal investigator 1 Amgen Inc. $18,757.80 04/24/2025 Non-covered Recipient Entity
DRS ITELD BERNSTEIN & ASSOC DBA LA HEART CTR
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246640877
Principal investigator 1 Boehringer Ingelheim International GmbH $299.70 04/23/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628747
Principal investigator 1 Boehringer Ingelheim International GmbH $1.55 04/23/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628749
Principal investigator 1 Janssen Research & Development, LLC $5,538.00 04/23/2025 Non-covered Recipient Entity
Louisiana Heart Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224827
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628721
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628723
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 03/25/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628717
Principal investigator 1 Boehringer Ingelheim International GmbH $2.82 03/25/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628719
Principal investigator 1 Janssen Research & Development, LLC $6,124.00 03/21/2025 Non-covered Recipient Entity
Louisiana Heart Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224744
Principal investigator 1 Boehringer Ingelheim International GmbH $2,828.00 03/19/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628703
Principal investigator 1 Boehringer Ingelheim International GmbH $206.00 03/19/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628705
Principal investigator 1 Boehringer Ingelheim International GmbH $2,310.00 03/19/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628707
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 03/13/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994413
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628697
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628699
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,284.50 02/27/2025 Non-covered Recipient Entity
ITELD BERNSTEIN ASSOCIATES DBA LOUISIANA HEART CENTER
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190303511
Principal investigator 1 Boehringer Ingelheim International GmbH $239.76 02/25/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628709
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 02/25/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628711
Principal investigator 1 Boehringer Ingelheim International GmbH $2.61 02/25/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628713
Principal investigator 1 Boehringer Ingelheim International GmbH $6.58 02/25/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628715
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,224.80 02/20/2025 Non-covered Recipient Entity
ITELD BERNSTEIN ASSOCIATES DBA LOUISIANA HEART CENTER
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190303517
Principal investigator 1 Janssen Research & Development, LLC $11,399.00 02/19/2025 Non-covered Recipient Entity
Louisiana Heart Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224803
Principal investigator 1 Novartis Pharmaceuticals Corporation $30,936.46 02/03/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190302099
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628693
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628695
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628701
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,880.20 01/30/2025 Non-covered Recipient Entity
ITELD BERNSTEIN ASSOCIATES DBA LOUISIANA HEART CENTER
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190303509
Principal investigator 1 Boehringer Ingelheim International GmbH $2,179.00 01/22/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628687
Principal investigator 1 Janssen Research & Development, LLC $5,963.00 01/22/2025 Non-covered Recipient Entity
Louisiana Heart Ctr
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224843
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,708.47 01/15/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER RESEARCH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190309218
Principal investigator 1 Eli Lilly and Company $2,223.09 01/09/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187884506
Principal investigator 1 Amgen Inc. $433.04 01/08/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
OCEAN(a)-Outcomes Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction Outcomes trial No dispute reported 06/30/2026 1246643667
Principal investigator 1 Eli Lilly and Company $113,460.00 01/07/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187884182
Principal investigator 1 Novartis Pharmaceuticals Corporation $33,904.65 01/06/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190309216
Principal investigator 1 Amgen Inc. $10,534.46 01/02/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER - HAMMOND
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246643649
Principal investigator 1 Amgen Inc. $13,906.20 01/02/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246643663
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628689
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220628691